Concentration of soluble urokinase plasminogen activator receptor (suPAR) in the pre-ovulatory follicular fluid is associated with development of ovarian hyperstimulation syndrome during ovarian stimulation
| Autor: | M Toftager, Jeanette Bogstad, C. Yding Andersen, Lisbeth Prætorius, Anja Pinborg, Kristine Løssl, Søren Schwartz Sørensen, Anne Zedeler, Anna G.-A. Grynnerup, Marie Louise Grøndahl |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Adult
Ovulation 0301 basic medicine Placental growth factor Ovarian hyperstimulation syndrome Fertilization in Vitro Receptors Urokinase Plasminogen Activator Andrology Ovarian Hyperstimulation Syndrome 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Ovulation Induction Genetics Humans Medicine Assisted Reproduction Technologies Receptor Genetics (clinical) 030219 obstetrics & reproductive medicine business.industry Obstetrics and Gynecology General Medicine medicine.disease Follicular fluid Pathophysiology Follicular Fluid Vascular endothelial growth factor 030104 developmental biology Solubility Reproductive Medicine SuPAR chemistry Oocytes Female business Plasminogen activator Developmental Biology |
| Zdroj: | Journal of Assisted Reproduction and Genetics. 35:2187-2193 |
| ISSN: | 1573-7330 1058-0468 |
| Popis: | PURPOSE: Investigating whether pre-ovulatory follicular fluid (FF) levels of selected proteins differ between women who do or do not develop severe ovarian hyperstimulation syndrome (OHSS) and evaluate whether they potentially could guide a “freeze-all” strategy. METHODS: FF was collected during a randomized controlled trial comparing OHSS in antagonist versus agonist protocol including 1050 women in their first assisted reproductive technology (ART) cycle during year 2009–2013. The present sub-study is a matched case-control study comparing FF levels of soluble urokinase plasminogen activator receptor (suPAR), C-reactive protein, placental growth factor, vascular endothelial growth factor, and angiopoietins 1 and 2 in OHSS cases (n = 25, severe OHSS, and ≥ 15 oocytes), high-risk controls (n = 25, no OHSS, and ≥ 15 oocytes), and low-risk controls (n = 25, no OHSS, and 5–8 oocytes). RESULTS: FF level of suPAR differed significantly between the three groups (p = 0.018) with mean (SD) levels of 2.3 (0.4) μg/L, 2.6 (0.8) μg/L, and 2.8 (0.6) μg/L in OHSS cases, high-risk controls, and low-risk controls, respectively. Receiver operating characteristic curve analysis demonstrated that suPAR levels could predict severe OHSS (AUC 0.678; 95% CI 0.553–0.803) with a sensitivity of 64% and a specificity of 66%. None of the other investigated proteins differed between the three groups or between OHSS cases and combined controls. CONCLUSION: The pre-ovulatory FF level of suPAR was significantly lower in women developing severe OHSS, indicating that the plasminogen activator system could be involved in the pathophysiology of OHSS. However, suPAR did not provide a satisfying predictive value for the prediction of OHSS. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink